News

Hosts Nancy Reau and Kimberly Brown are joined by Mary Rinella to discuss the evolving MASH treatment landscape with GLP-1s and FGF21s in development.

A series of phase 2/3 trials collectively indicate the overall lipid-lowering effects of obicetrapib in a 5 mg dose, a 10 mg dose, and 10 mg with ezetimibe.

A study reveals that upadacitinib dose adjustments in atopic dermatitis enhance treatment personalization.

Single-dose psychedelic therapy (RE104 30 mg) shows rapid improvements in postpartum depression, offering a potential alternative to slow-acting therapies.

This episode focuses on latest advancements in CGM and diabetes management from the ADCES 2025 annual meeting.

New research shines a light on the liver’s role in cardiovascular disease prevention, indicating a potential new predictor for coronary heart disease.

In this analysis, investigators looked into age-stratified impacts of rivaroxaban as a monotherapy versus the impacts of rivaroxaban plus antiplatelet agent combination treatment.

Finerenone reduced diuretic needs while improving outcomes across various diuretic therapies.

A review estimated that eliminating cerebrovascular disease could have prevented 1.5 to 1.8 million US dementia cases in 2020.

Semaglutide 2.4 mg use was linked to lower medical costs and inpatient resource utilization among patients with overweight or obesity and heart failure.

A recent study from Korea has drawn connections between sleep duration and regularity and major adverse cardiovascular events.

Survey reveals persistent misconceptions about blood pressure thresholds, symptoms, and management, with most patients willing to act on clinician advice.

This study suggests a causative role of left bundle branch block (LBBB) in patients’ progression to heart failure.

The new guidelines, updated from 2015, are informed by 194 systematic reviews, and 133 RCTs.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, sit down with Darren McGuire, MD, to discuss the results of this groundbreaking trial.

This analysis of patients with atopic dermatitis in the BIOREP registry spotlight the safety and efficacy of lebrikizumab therapy.

Multicenter study finds most children with anaphylaxis can be safely discharged within 2 hours, with 4 hours for those with cardiovascular involvement.

Hydroxychloroquine reduced proteinuria levels with an acceptable safety profile but had limited effects on overall eGFR in primary glomerular diseases.

This episode includes a breakdown of topline data from ATTAIN-1 and part 1 of the recap for ADCES 2025.

An audio recap of the top 5 stories in healthcare news from the week of 08/10-08/16.

This HCPLive Five episode focuses on 5 key ophthalmology updates from the ASRS2025 conference.

A new advisory highlights cephalexin’s efficacy and low cross-reactivity risk, supporting its safe use in patients with penicillin allergy.

This analysis suggests that GLP-1 RAs provide promise for those with HS and obesity and potentially for such individuals without obesity via immunological impacts.

ACHIEVE trial data showed spironolactone 25 mg did not reduce cardiovascular mortality and hospitalization due to heart failure in dialysis patients.

The TITRATE-HF study highlights the importance of early and intensive use of guideline-recommended medical therapy, focusing on dose titration.

The G-EPOSS study demonstrated the long-term impacts of guselkumab on patients’ psoriasis symptoms, sexual impairment, and perceived stigmatization.

New research confirms that adrenaline is safe and effective for anaphylaxis, debunking myths.